Travere Therapeutics, Inc. $TVTX Shares Sold by Engineers Gate Manager LP

Posted by Geri Gentry on Sep 15th, 2026

Engineers Gate Manager LP lowered its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 81.5% in the second quarter, Holdings Channel reports. The firm owned 47,003 shares of the company’s stock after selling 207,398 shares during the period. Engineers Gate Manager LP’s holdings in Travere Therapeutics were worth $2,670,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC raised its position in shares of Travere Therapeutics by 53.4% during the 2nd quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock worth $34,000 after purchasing an additional 211 shares during the last quarter. Fifth Third Bancorp acquired a new stake in Travere Therapeutics in the 1st quarter worth about $35,000. Comerica Bank boosted its holdings in Travere Therapeutics by 77.5% in the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock worth $43,000 after buying an additional 492 shares during the last quarter. Allworth Financial LP acquired a new stake in Travere Therapeutics in the 2nd quarter worth about $47,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Travere Therapeutics during the 2nd quarter worth approximately $70,000.

Analysts Set New Price Targets

A number of brokerages have commented on TVTX. Wells Fargo & Company increased their target price on Travere Therapeutics from $50.00 to $65.00 and gave the company an “overweight” rating in a report on Friday, June 12th. Weiss Ratings lowered Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Canaccord Genuity Group boosted their price target on Travere Therapeutics from $62.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. HC Wainwright increased their price objective on Travere Therapeutics from $57.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Finally, Evercore set a $78.00 price objective on Travere Therapeutics in a report on Monday, August 10th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Travere Therapeutics has an average rating of “Moderate Buy” and an average target price of $68.00.

Get Our Latest Stock Report on TVTX

Travere Therapeutics Stock Down 0.6%

NASDAQ TVTX opened at $65.79 on Tuesday. Travere Therapeutics, Inc. has a 52 week low of $22.06 and a 52 week high of $68.73. The company has a quick ratio of 3.99, a current ratio of 4.05 and a debt-to-equity ratio of 24.58. The business’s fifty day simple moving average is $61.31 and its 200-day simple moving average is $47.79. The firm has a market cap of $6.20 billion, a PE ratio of -143.02 and a beta of 1.05.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.03. Travere Therapeutics had a negative net margin of 7.35% and a negative return on equity of 55.15%. The firm had revenue of $169.58 million for the quarter, compared to analysts’ expectations of $157.27 million. During the same quarter in the previous year, the company posted $0.13 EPS. The company’s revenue was up 48.2% compared to the same quarter last year. As a group, equities analysts anticipate that Travere Therapeutics, Inc. will post -0.54 earnings per share for the current year.

Insider Buying and Selling

In other Travere Therapeutics news, Director Jeffrey Meckler sold 20,000 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $67.31, for a total value of $1,346,200.00. Following the transaction, the director directly owned 91,500 shares in the company, valued at $6,158,865. The trade was a 17.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.44% of the stock is owned by company insiders.

Travere Therapeutics Company Profile

(Free Report)

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.